close search

Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis.

Achar J, Hewison C, Cavalheiro AP, Skrahina A, Cajazeiro J, Nargiza P, Herboczek K, Rajabov AS, Hughes J, Ferlazzo G, Seddon JA, du Cros P

VIEW FULL ARTICLE

  • Journal Emerging infectious diseases

  • Published 17 Oct 2017

  • Volume 23

  • ISSUE 10

  • Pagination 1711-3

  • DOI 10.3201/eid2310.170303

Abstract

We describe 27 children and adolescents <18 years of age who received bedaquiline during treatment for multidrug-resistant tuberculosis. We report good treatment responses and no cessation attributable to adverse effects. Bedaquiline could be considered for use with this age group for multidrug-resistant tuberculosis when treatment options are limited.